Physician profile
Paul E Kim
NPI 1871517110
$8,192.95
in general payments reported to CMS, 2019-2025
36 companies · $825 in 2025
The $825 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,799 · 2020: $1,098 · 2021: $1,146 · 2022: $939 · 2023: $928 · 2024: $458 · 2025: $825.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622 · Travel and Lodging: $554 · Education: $35.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.48 |
| Travel and Lodging | $554.00 |
| Education | $35.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,885.35 | 2019-2025 | Wavewriter Alpha Prime 16, General - Endochoice, Intracept |
| Abbott Laboratories | $1,491.60 | 2019-2025 | Octrode, Proclaim, Eterna |
| Vertiflex, INC. | $1,270.91 | 2019 | |
| Nevro Corp. | $734.02 | 2019-2024 | Senza |
| Alphatec Spine, INC | $554.00 | 2025 | Other - Miscellaneous |
| Stimwave Technologies Incorporated | $475.59 | 2019-2021 | |
| Medtronic, INC. | $202.93 | 2023-2024 | Mazor X System, Accurian, Catalyft Pl Expandable Interbody System |
| Daiichi Sankyo INC. | $125.49 | 2019 | |
| Medtronic USA, INC. | $123.16 | 2019 | |
| Biotissue Holdings INC. | $121.40 | 2023 | |
| Lilly USA, LLC | $120.41 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $110.31 | 2021 | |
| Arbor Pharmaceuticals, INC. | $109.74 | 2019-2021 | |
| Eisai INC. | $74.05 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $70.65 | 2020-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $68.00 | 2022 | |
| Scilex Pharmaceuticals INC. | $56.13 | 2019 | |
| Si-Bone, INC. | $55.87 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $54.27 | 2019-2021 | |
| Redhill Biopharma INC. | $46.75 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.54 | 2022 | |
| Bausch Health US, LLC | $42.14 | 2019 | |
| Abbvie INC. | $41.92 | 2023 | |
| Idorsia Pharmaceuticals US INC | $36.20 | 2023 | Quviviq |
| Curonix LLC | $35.32 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $33.87 | 2023-2024 | Nalu Neurostimulation System |
| Amgen INC. | $30.69 | 2021 | |
| Painteq LLC | $28.15 | 2024 | Painteq |
| Depuy Synthes Sales INC. | $27.17 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $24.42 | 2020 | |
| Forte Bio-Pharma LLC | $20.98 | 2024 | Prolate, Nalocet |
| Teva Pharmaceuticals USA, INC. | $17.82 | 2021 | |
| Merz North America, INC. | $16.44 | 2019 | |
| Shionogi INC | $14.18 | 2019 | |
| Medline Industries LP | $13.49 | 2024 | |
| Pfizer INC. | $12.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.